Critical Limb Ischemia - Pipeline Review, H2 2017

Date: October 31, 2017
Pages: 120
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C3216347D5CEN
Leaflet:

Download PDF Leaflet

Critical Limb Ischemia - Pipeline Review, H2 2017
Critical Limb Ischemia - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Critical Limb Ischemia - Pipeline Review, H2 2017, provides an overview of the Critical Limb Ischemia (Cardiovascular) pipeline landscape.

Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that result in reduced blood flow to the legs, feet and hands. Symptoms include pain or numbness in feet or toes, sores, skin infections will not heal. Treatment goals for CLI include reducing the number of cardiovascular risk factors (such as quitting smoking and reduction of cholesterol), relieving pain, healing ulcers, preventing major amputation, improving quality of life and increasing survival.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Critical Limb Ischemia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Critical Limb Ischemia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Critical Limb Ischemia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Critical Limb Ischemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 13, 4, 1 and 10 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Critical Limb Ischemia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Critical Limb Ischemia (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Critical Limb Ischemia (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Critical Limb Ischemia (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Critical Limb Ischemia (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Critical Limb Ischemia (Cardiovascular)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Critical Limb Ischemia (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Critical Limb Ischemia (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Global Markets Direct Report Coverage
Critical Limb Ischemia - Overview
Critical Limb Ischemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Critical Limb Ischemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Critical Limb Ischemia - Companies Involved in Therapeutics Development
AnGes MG Inc
apceth Biopharma GmbH
Athersys Inc
BiogenCell Ltd
Caladrius Biosciences Inc
Cynata Therapeutics Ltd
Hemostemix Inc
Histocell SL
ID Pharma Co Ltd
Integene International Holdings LLC
Juventas Therapeutics Inc
Kang Stem Biotech Co Ltd
Kasiak Research Pvt Ltd
Neurofx Inc
Nissan Chemical Industries Ltd
Pharmicell Co Ltd
Pluristem Therapeutics Inc
ReNeuron Group Plc
Symic Biomedical Inc
TikoMed AB
U.S. Stem Cell Inc
VESSL Therapeutics Ltd
ViroMed Co Ltd
Critical Limb Ischemia - Drug Profiles
ACP-01 - Drug Profile
AdipoCell - Drug Profile
Alecmestencel-T - Drug Profile
ASCT-01 - Drug Profile
beperminogene perplasmid - Drug Profile
BGC-101 - Drug Profile
Biologic to Activate FGF2 for Critical Limb Ischemia - Drug Profile
Cell Therapy for Peripheral Arterial Disease and Coronary Artery Diseases - Drug Profile
Cellgram-CLI - Drug Profile
CLBS-12 - Drug Profile
DVC-10101 - Drug Profile
Gene Therapy for Critical Limb Ischemia - Drug Profile
HC-016 - Drug Profile
JVS-100 - Drug Profile
NFx-101 - Drug Profile
NK-104 NP - Drug Profile
PF-05285401 - Drug Profile
PLX-PAD - Drug Profile
Procell - Drug Profile
Protein to Agonize LRP5 and LRP6 for Critical Limb Ischemia and Myocardial Infarction - Drug Profile
Refacell-CLI - Drug Profile
Rejuveinix - Drug Profile
ReN-009 - Drug Profile
SB-030 - Drug Profile
Stem Cell Therapy for Cardiovacular Diseases - Drug Profile
Stem Cell Therapy for Critical Limb Ischemia - Drug Profile
Stem Cell Therapy for Critical Limb Ischemia - Drug Profile
Stem Cell Therapy for Critical Limb Ischemia - Drug Profile
TM-700 - Drug Profile
TXA-302 - Drug Profile
VM-202 - Drug Profile
Critical Limb Ischemia - Dormant Projects
Critical Limb Ischemia - Discontinued Products
Critical Limb Ischemia - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Critical Limb Ischemia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Critical Limb Ischemia - Pipeline by AnGes MG Inc, H2 2017
Critical Limb Ischemia - Pipeline by apceth Biopharma GmbH, H2 2017
Critical Limb Ischemia - Pipeline by Athersys Inc, H2 2017
Critical Limb Ischemia - Pipeline by BiogenCell Ltd, H2 2017
Critical Limb Ischemia - Pipeline by Caladrius Biosciences Inc, H2 2017
Critical Limb Ischemia - Pipeline by Cynata Therapeutics Ltd, H2 2017
Critical Limb Ischemia - Pipeline by Hemostemix Inc, H2 2017
Critical Limb Ischemia - Pipeline by Histocell SL, H2 2017
Critical Limb Ischemia - Pipeline by ID Pharma Co Ltd, H2 2017
Critical Limb Ischemia - Pipeline by Integene International Holdings LLC, H2 2017
Critical Limb Ischemia - Pipeline by Juventas Therapeutics Inc, H2 2017
Critical Limb Ischemia - Pipeline by Kang Stem Biotech Co Ltd, H2 2017
Critical Limb Ischemia - Pipeline by Kasiak Research Pvt Ltd, H2 2017
Critical Limb Ischemia - Pipeline by Neurofx Inc, H2 2017
Critical Limb Ischemia - Pipeline by Nissan Chemical Industries Ltd, H2 2017
Critical Limb Ischemia - Pipeline by Pharmicell Co Ltd, H2 2017
Critical Limb Ischemia - Pipeline by Pluristem Therapeutics Inc, H2 2017
Critical Limb Ischemia - Pipeline by ReNeuron Group Plc, H2 2017
Critical Limb Ischemia - Pipeline by Symic Biomedical Inc, H2 2017
Critical Limb Ischemia - Pipeline by TikoMed AB, H2 2017
Critical Limb Ischemia - Pipeline by U.S. Stem Cell Inc, H2 2017
Critical Limb Ischemia - Pipeline by VESSL Therapeutics Ltd, H2 2017
Critical Limb Ischemia - Pipeline by ViroMed Co Ltd, H2 2017
Critical Limb Ischemia - Dormant Projects, H2 2017
Critical Limb Ischemia - Dormant Projects, H2 2017 (Contd.1), H2 2017
Critical Limb Ischemia - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Critical Limb Ischemia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

AnGes MG Inc
apceth Biopharma GmbH
Athersys Inc
BiogenCell Ltd
Caladrius Biosciences Inc
Cynata Therapeutics Ltd
Hemostemix Inc
Histocell SL
ID Pharma Co Ltd
Integene International Holdings LLC
Juventas Therapeutics Inc
Kang Stem Biotech Co Ltd
Kasiak Research Pvt Ltd
Neurofx Inc
Nissan Chemical Industries Ltd
Pharmicell Co Ltd
Pluristem Therapeutics Inc
ReNeuron Group Plc
Symic Biomedical Inc
TikoMed AB
U.S. Stem Cell Inc
VESSL Therapeutics Ltd
ViroMed Co Ltd
Skip to top


Ask Your Question

Critical Limb Ischemia - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: